BioPharma Credit
Market Cap
US$1.3b
Last Updated
2021/03/06 20:05 UTC
Data Sources
Company Financials
Executive Summary
BioPharma Credit PLC, a specialist life sciences debt investment trust, primarily invests in interest-bearing debt assets. More Details
Rewards
Risk Analysis
Snowflake Analysis
Flawless balance sheet and fair value.
Share Price & News
How has BioPharma Credit's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: BPCR is less volatile than 75% of UK stocks over the past 3 months, typically moving +/- 1% a week.
Volatility Over Time: BPCR's weekly volatility (1%) has been stable over the past year.
Market Performance
7 Day Return
-0.4%
BPCR
-5.6%
GB Capital Markets
1.2%
GB Market
1 Year Return
-1.4%
BPCR
11.2%
GB Capital Markets
4.6%
GB Market
Return vs Industry: BPCR underperformed the UK Capital Markets industry which returned 11.2% over the past year.
Return vs Market: BPCR underperformed the UK Market which returned 4.6% over the past year.
Shareholder returns
| BPCR | Industry | Market | |
|---|---|---|---|
| 7 Day | -0.4% | -5.6% | 1.2% |
| 30 Day | -2.0% | -6.6% | 0.9% |
| 90 Day | -0.1% | 0.06% | 2.4% |
| 1 Year | 4.0%-1.4% | 14.8%11.2% | 10.6%4.6% |
| 3 Year | 16.2%-5.2% | 39.5%23.7% | 8.6%-4.5% |
| 5 Year | n/a | 99.0%65.5% | 39.5%12.5% |
Long-Term Price Volatility Vs. Market
How volatile is BioPharma Credit's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 years ago | Simply Wall St
What Does BioPharma Credit PLC's (LON:BPCR) PE Ratio Tell You?Valuation
Is BioPharma Credit undervalued compared to its fair value and its price relative to the market?
16.2x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: BPCR ($0.98) is trading above our estimate of fair value ($0.86)
Significantly Below Fair Value: BPCR is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: BPCR is good value based on its PE Ratio (16.2x) compared to the GB Capital Markets industry average (20.1x).
PE vs Market: BPCR is good value based on its PE Ratio (16.2x) compared to the UK market (24.1x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BPCR's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BPCR is good value based on its PB Ratio (1x) compared to the GB Capital Markets industry average (1.6x).
Next Steps
Future Growth
How is BioPharma Credit forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
24.8%
Forecasted Diversified Financials industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as BioPharma Credit has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Next Steps
- Examine whether BioPharma Credit is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
- BioPharma Credit competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Diversified Financials industry.
Past Performance
How has BioPharma Credit performed over the past 5 years?
-28.0%
Last years earnings growth
Earnings and Revenue History
Quality Earnings: BPCR has high quality earnings.
Growing Profit Margin: BPCR's current net profit margins (73.6%) are lower than last year (80.9%).
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if BPCR's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: BPCR's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: BPCR had negative earnings growth (-28%) over the past year, making it difficult to compare to the Capital Markets industry average (-1.9%).
Return on Equity
High ROE: BPCR's Return on Equity (6%) is considered low.
Next Steps
Financial Health
How is BioPharma Credit's financial position?
Financial Position Analysis
Short Term Liabilities: BPCR's short term assets ($64.3M) exceed its short term liabilities ($31.4M).
Long Term Liabilities: BPCR's short term assets ($64.3M) exceed its long term liabilities ($564.0K).
Debt to Equity History and Analysis
Debt Level: BPCR is debt free.
Reducing Debt: BPCR has not had any debt for past 5 years.
Debt Coverage: BPCR has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: BPCR has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Next Steps
Dividend
What is BioPharma Credit current dividend yield, its reliability and sustainability?
8.48%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: BPCR's dividend (8.48%) is higher than the bottom 25% of dividend payers in the UK market (1.49%).
High Dividend: BPCR's dividend (8.48%) is in the top 25% of dividend payers in the UK market (4.51%)
Stability and Growth of Payments
Stable Dividend: Whilst dividend payments have been stable, BPCR has been paying a dividend for less than 10 years.
Growing Dividend: BPCR's dividend payments have increased, but the company has only paid a dividend for 3 years.
Current Payout to Shareholders
Dividend Coverage: With its high payout ratio (116.2%), BPCR's dividend payments are not well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.3yrs
Average board tenure
CEO
BioPharma Credit has no CEO, or we have no data on them.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Non-Executive Director | 0.50yr | no data | 0.0073% $ 97.6k | |
| Independent Chairman | 0.50yr | US$72.84k | 0.0075% $ 100.0k | |
| Independent Director | 4.42yrs | US$70.00k | 0.0073% $ 97.6k | |
| Independent Director | 4.33yrs | US$85.00k | 0.0073% $ 97.6k | |
| Independent Non-Executive Director | 2.25yrs | US$79.78k | no data |
2.3yrs
Average Tenure
62yo
Average Age
Experienced Board: BPCR's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
BioPharma Credit PLC's company bio, employee growth, exchange listings and data sources
Key Information
- Name: BioPharma Credit PLC
- Ticker: BPCR
- Exchange: LSE
- Founded: 2016
- Industry: Asset Management and Custody Banks
- Sector: Diversified Financials
- Market Cap: US$1.341b
- Shares outstanding: 1.37b
- Website: https://www.bpcruk.com
Location
- BioPharma Credit PLC
- Beaufort House
- 51 New North Road
- Exeter
- Devon
- EX4 4EP
- United Kingdom
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| BPCR | LSE (London Stock Exchange) | Yes | Ordinary Shares | GB | USD | Mar 2017 |
| B3P | MUN (Boerse Muenchen) | Yes | Ordinary Shares | DE | EUR | Mar 2017 |
| BPCRL | BATS-CHIXE (BATS 'Chi-X Europe') | Yes | Ordinary Shares | GB | USD | Mar 2017 |
| BOPC.F | OTCPK (Pink Sheets LLC) | Yes | Ordinary Shares | US | USD | Mar 2017 |
Biography
BioPharma Credit PLC, a specialist life sciences debt investment trust, primarily invests in interest-bearing debt assets. Its assets are secured by royalties or other cash flows derived from the sales of ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/03/06 20:05 |
| End of Day Share Price | 2021/03/05 00:00 |
| Earnings | 2020/06/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.